Trials / Recruiting
RecruitingNCT06122831
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
A Phase Ib/II Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Intermediate- and High-risk Myelofibrosis
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ05105 Tablets | TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor. |
| DRUG | TQB3617 Capsules | TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor |
Timeline
- Start date
- 2023-12-12
- Primary completion
- 2026-12-01
- Completion
- 2027-04-01
- First posted
- 2023-11-08
- Last updated
- 2025-12-08
Locations
22 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06122831. Inclusion in this directory is not an endorsement.